- Home
- NEXM vs IMA Comparison
NEXM vs IMA Comparison
Compare NEXM & IMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | NEXM | IMA |
|---|---|---|
| Founded | N/A | 2019 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 78.4M | 66.3M |
| IPO Year | 2002 | 2021 |
Fundamental Metrics
Financial Performance| Metric | NEXM | IMA |
|---|---|---|
| Price | $1.89 | $4.60 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 2 | 4 |
| Target Price | $7.42 | ★ $18.00 |
| AVG Volume (30 Days) | ★ 32.2K | 12.3K |
| Earning Date | 11-12-2026 | 11-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 1044.00 | N/A |
| EPS | ★ 0.63 | N/A |
| Revenue | N/A | ★ $800,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $3.06 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.90 | $3.94 |
| 52 Week High | $6.65 | $9.10 |
Technical Indicators
Market Signals| Indicator | NEXM | IMA |
|---|---|---|
| Relative Strength Index (RSI) | 34.51 | 30.75 |
| Support Level | N/A | $3.94 |
| Resistance Level | $2.39 | $6.13 |
| Average True Range (ATR) | 0.11 | 0.25 |
| MACD | -0.04 | -0.01 |
| Stochastic Oscillator | 22.96 | 1.22 |
Price Performance
Historical ComparisonAbout NEXM NexMetals Mining Corp.
NexMetals Mining Corp is a mineral exploration and development company focused on discovering and advancing high-quality copper-nickel-cobalt-platinum element metals (Cu- Cu-Ni-Co-PGE) resources. The group prioritizes projects in stable, mining-friendly jurisdictions with supportive foreign investment and rule-of-law standards. Its projects are Botswana and Canada.
About IMA ImageneBio Inc.
ImageneBio Inc is a clinical-stage biopharmaceutical company developing therapeutics for patients with immunological, autoimmune and inflammatory diseases. The company's flagship asset, IMG-007, is a non-depleting anti-OX40 monoclonal antibody that binds specifically to OX40 receptor on activated T cells to block receptor binding to OX40 ligand (OX40L). IMG-007 is being developed to potentially treat multiple autoimmune and inflammatory diseases and disorders. The company operates in a single segment.